Tejasav Sehrawat, MD
LightNews LightNews
tejasavsehrawat.bsky.social
Tejasav Sehrawat, MD
@tejasavsehrawat.bsky.social
14 followers 23 following 0 posts
Resident and Incoming Gastroenterology Fellow @ Yale School of Medicine | Serving AASLD Steering Committees and AGA Hepatobiliary Council | Prior PostDoc @ MayoClinic and GMCH
Posts Replies Media Videos
Reposted by Tejasav Sehrawat, MD
yaleschoolofmed.bsky.social
YSM researchers have developed a cost-effective new #test to search for #mutations that cause dystroglycanopathies, a group of rare and life-threatening #genetic disorders: medicine.yale.edu/news-article...
December 3, 2024 at 2:56 PM
Reposted by Tejasav Sehrawat, MD
yaleschoolofmed.bsky.social
In a new study published in Nature #Cancer, YSM researchers find ORACLE, a new genetic test performed on #tumors, can better predict patient survival with #lungcancer – even at the earliest stages of disease. @nature.com

brnw.ch/21wQ24B
January 15, 2025 at 8:20 PM
Reposted by Tejasav Sehrawat, MD
lancetgastrohep.bsky.social
New research - Artenie et al - Global, regional, and national estimates of HCV infection incidence among people who inject drugs and number of new annual HCV infections attributable to injecting drug use: a multi-stage analysis

www.thelancet.com/journals/lan...

#LiverSky #IDSky #MedSky #HepSky
Global, regional, and national estimates of hepatitis C virus (HCV) infection incidence among people who inject drugs and number of new annual HCV infections attributable to injecting drug use: a mult...
A substantial increase in HCV treatment and prevention is needed globally to achieve the WHO 2030 HCV elimination target for incidence among PWID.
www.thelancet.com
February 25, 2025 at 12:37 PM
Reposted by Tejasav Sehrawat, MD
natrevgastrohep.nature.com
ICYMI: New online! AI-enabled ‘endo-histo-omics’: breaking down intestinal barriers in IBD
AI-enabled ‘endo-histo-omics’: breaking down intestinal barriers in IBD
Nature Reviews Gastroenterology & Hepatology, Published online: 03 March 2025; doi:10.1038/s41575-025-01051-1The AI-driven ‘endo-histo-omics’ approach integrates clinical, endoscopic, histological and molecular data to improve management of inflammatory…
www.nature.com
March 9, 2025 at 5:43 PM
Reposted by Tejasav Sehrawat, MD
jhepatology.bsky.social
🆕Article in press❕

A phase IIb randomised-controlled trial of the FFAR1/FFAR4 agonist icosabutate in MASH

Full text here👉https://bit.ly/4iucrzV

More information here👉https://bwnews.pr/4hadNie

#OpenAccess
#LiverSky
March 6, 2025 at 3:19 PM
Reposted by Tejasav Sehrawat, MD
easlnews.bsky.social
The authors of today’s #readoftheweek📚 developed an automated system using CD8-stained whole-slide images to assess immune infiltration (ATLS-8) in patients with #HCC.

Read here this JHEP Reports article: www.jhep-reports.eu/article/S258...

#LiverSky
March 6, 2025 at 2:09 PM
Reposted by Tejasav Sehrawat, MD
mezzc.bsky.social
How do we apply the new SLD definitions in research? To study outcomes and implement trials for different SLD subtypes, we first need to be able to accurately identify each clinical entity using medical records/registry data.
www.cghjournal.org/article/S154...

@amergastroassn.bsky.social
December 16, 2024 at 1:07 PM
Reposted by Tejasav Sehrawat, MD
insight.jci.org
ASCI member @jasmohanbajaj.bsky.social et al. show that fecal transplant ameliorates a source of cirrhosis progression.
JCI Insight - Intestinal mucosal mitochondrial oxidative phosphorylation worsens with cirrhosis progression and is ameliorated with FMT
Research LetterIn-Press PreviewHepatologyMicrobiology Open Access | 10.1172/jci.insight.186649
buff.ly
February 27, 2025 at 4:13 PM
Reposted by Tejasav Sehrawat, MD
jasmohanbajaj.bsky.social
Thanks #CDDW #CLM Chris Rose & Premsyl Bercik for the invite to speak in a beautiful but freezing Quebec city on #HE #microbes & #gutbrainaxis. Excellent joint session with #microbiology & #gi expertise. 🇨🇦 warmth shone thru despite the polar vortex!! @vculiver.bsky.social
March 2, 2025 at 2:30 PM
Reposted by Tejasav Sehrawat, MD
amergastroassn.bsky.social
Our latest clinical practice update offers 1️⃣1️⃣ tips to help you evaluate and manage portal vein thrombosis in cirrhosis patients. Watch @drjessicadavis.bsky.social and Fadi Francis discuss management strategies. https://buff.ly/40Y66Wc

#Cirrhosis #Liversky
February 21, 2025 at 2:00 PM
Reposted by Tejasav Sehrawat, MD
amergastroassn.bsky.social
📢Updated recommendations by Multi-Society Task Force on bowel preparation quality for #colonoscopy: buff.ly/XwcFL6Y

MSTFCRC = @amergastroassn.bsky.social @asgeendo.bsky.social and @amcollegegastro.bsky.social

@swatipatelmd.bsky.social @aasmashaukatmd.bsky.social @drfolamay.bsky.social
March 4, 2025 at 4:01 PM
Reposted by Tejasav Sehrawat, MD
blaneymd.medsky.social
Seeing high MELD patients w/ ALD who re-compensate with sobriety & get their lives back (and avoid transplant!) is incredibly rewarding. As Hepatologists treating ALD, it is essential that we treat the underlying alcohol use disorder so our patients can improve! @juanpabloarab.bsky.social #liversky
December 9, 2024 at 8:22 PM
Reposted by Tejasav Sehrawat, MD
juanpabloarab.bsky.social
We are pleased to share our article Metabolic Dysfunction and Alcohol-related Liver Disease (MetALD): Position statement by an expert panel on alcohol-related liver disease. Now available online in
@jhepatology.bsky.social
@MATHURINPHILIP1

#LiverSky #LiverSky authors.elsevier.com/a/1kOr5cOnAU...
authors.elsevier.com
January 7, 2025 at 2:27 PM
Reposted by Tejasav Sehrawat, MD
vinayjaha.bsky.social
Team VCU at AASLD MASLD/MetALD/ALD Emerging Topic Conference 2025, Las Vegas

@juanpabloarab.bsky.social @saulkarpen.bsky.social @vculiver.bsky.social
March 2, 2025 at 5:46 PM
Reposted by Tejasav Sehrawat, MD
amcollegegastro.bsky.social
ACG recommends #ColorectalCancerScreening starting at age 45 for average risk adults

#Colonoscopy with polyp removal can prevent colorectal cancer

Learn more about screening: gi.org/ColonCancer

#ColorectalCancerAwarenessMonth
#Gastroenterology #GastroSky
March 10, 2025 at 1:49 PM
Reposted by Tejasav Sehrawat, MD
amcollegegastro.bsky.social
💙This talented crew is true #BlueForCRC on #DressInBlueDay

ACG’s dedicated staff is committed to:
💪 advancing #ColorectalCancerPrevention
💪advocating for #Gastroenterology clinicians
💪supporting the #ACGfamily
💪improving #Colonoscopy quality

#ColorectalCancerAwarenessMonth
#GastroSky
March 7, 2025 at 3:28 PM
Reposted by Tejasav Sehrawat, MD
ebtapper.bsky.social
When I treat autoimmune hepatitis, I start at 20mg of prednisone and then I taper super slowly while the azathioprine (or MMF) takes effect

What do you do, #liversky?

Here’s a study that looks at rapid vs non-rapid tapers (retrospectively)

doi.org/10.1016/j.ja...
March 2, 2025 at 4:50 PM
Reposted by Tejasav Sehrawat, MD
ebtapper.bsky.social
I ❤️ this paper on fluid and diuresis effects on liver stiffness in people with Fontan 🫀

journals.lww.com/hepcomm/full...

#liversky #cardiosky
Effect of maneuvers, diuresis, and fluid administration on... : Hepatology Communications
, ultrasound 2D shear-wave elastography LSMs were acquired at baseline and after maximum inspiration, expiration, standing, handgrip, aerobic exercise, i.v. fluid (500 mL normal saline) administration...
journals.lww.com
March 4, 2025 at 1:05 PM